UK 2022 Consensus on Normal Tissue Dose-Volume Constraints for Oligometastatic, Primary Lung and Hepatocellular Carcinoma Stereotactic Ablative Radiotherapy.

Authors :: Diez P
Hanna GG
Aitken KL
van As N
Carver A
Colaco RJ
Conibear J
Dunne EM
Eaton DJ
Franks KN
Good JS
Harrow S
Hatfield P
Hawkins MA
Jain S
McDonald F
Patel R
Rackley T
Sanghera P
Tree A
Murray L
Source :: Clinical oncology (Royal College of Radiologists (Great Britain)) [Clin Oncol (R Coll Radiol)] 2022 May; Vol. 34 (5), pp. 288-300. Date of Electronic Publication: 2022 Mar 07.
Publication Year :: 2022
Abstract: The use of stereotactic ablative radiotherapy (SABR) in the UK has expanded over the past decade, in part as the result of several UK clinical trials and a recent NHS England Commissioning through Evaluation programme. A UK SABR Consortium consensus for normal tissue constraints for SABR was published in 2017, based on the existing literature at the time. The published literature regarding SABR has increased in volume over the past 5 years and multiple UK centres are currently working to develop new SABR services. A review and update of the previous consensus is therefore appropriate and timely. It is hoped that this document will provide a useful resource to facilitate safe and consistent SABR practice.<br /> (Copyright © 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.)

Subjects :: Consensus
England
Humans
Lung
Carcinoma, Hepatocellular radiotherapy
Carcinoma, Hepatocellular surgery
Liver Neoplasms radiotherapy
Liver Neoplasms surgery
Lung Neoplasms radiotherapy
Lung Neoplasms surgery
Radiosurgery

Language :: English
ISSN :: 1433-2981
Volume :: 34
Issue :: 5
Database :: MEDLINE
Journal :: Clinical oncology (Royal College of Radiologists (Great Britain))
Publication Type :: Academic Journal
Accession number :: 35272913
Full Text :: https://doi.org/10.1016/j.clon.2022.02.010

Full Text Access

Tools